Over four years have passed since the beginning of the COVID-19 pandemic. The scientific response has been rapid and effective, with many therapeutic monoclonal antibodies and small molecules developed for clinical use. However, given the ability for viruses to become resistant to antivirals, it is perhaps no surprise that the field has identified resistance to nearly all of these compounds. Here, we provide a comprehensive review of the resistance profile for each of these therapeutics. We hope that this resource provides an atlas for mutations to be aware of for each agent, particularly as a springboard for considerations for the next generation of antivirals. Finally, we discuss the outlook and thoughts for moving forward in how we continue to manage this, and the next, pandemic.

自 COVID-19 大流行开始以来，已经过去四年多了。科学反应迅速有效，许多治疗性单克隆抗体和小分子已开发用于临床。然而，考虑到病毒能够对抗病毒药物产生抗药性，该领域发现几乎所有这些化合物都具有抗药性，这也许并不奇怪。在这里，我们对每种疗法的耐药情况进行了全面审查。我们希望该资源为每种药物提供需要了解的突变图谱，特别是作为考虑下一代抗病毒药物的跳板。最后，我们讨论了如何继续管理这一流行病以及下一次流行病的前景和想法。